Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac Surgery

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Postoperative atrial fibrillation is a common complication after cardiac surgery with a rate of 30%. However, management of postoperative atrial fibrillation is controversial. Two strategies are recommended : heart rate control using a betablocker or rhythm control with amiodarone.

Landiolol is a new-generation beta-blocker with a short half-life, which was approved by the Haute Autorité de Santé to be used in perioperative supra-ventricular tachycardias.

Only one study compared landiolol to amiodarone in the perioperative setting, with a better hemodynamic tolerance and a higher rate of conversion to sinus rhythm with landiolol. However this was a single-center and retrospective study.

The aim of our multicenter randomized study is to compare the effectiveness of landiolol in reducing atrial fibrillation to sinus rhythm compared to amiodarone in the postoperative period after cardiac surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Caen
• Treatments: Amiodarone; Landiolol

Criteria

Inclusion Criteria:

• Adult patients hospitalized in the cardiac ICU after having undergone cardiac surgery (CABG, aortic valve or ascending aortic root replacement or a combination of both)

• New onset of atrial fibrillation lasting more than 30 minutes in the postoperative period after cardiac surgery

• French speaking patients

• Written consent

• Patients with social security insurance

Exclusion Criteria:

• Hemodynamic instability requiring electrical cardioversion of atrial fibrillation

• Sepsis

• Bradyarrythmia (< 90/min)

• Patients requiring inotropes in the postoperative period

• Patient with pre-existing atrial fibrillation

• Patient with anticoagulant therapy before surgery

• Contraindication to amiodarone or beta-blockers

• Urgent surgery (< 24h), ventricular assist device, heart transplant, TAVR, mechanical valve, mitral or tricuspid valve replacement.

• No written consent

• Pregnant women,

• Underaged patients (<18 years old)

• Patients not able to give consent (curators, patients deprived of public rights)